TNK-tissue plasminogen activator

a genetically-engineered variant of tissue plasminogen activator with amino acid substitutions at Thr(103) by Asn, Asn(117) by glutamine, and 4 amino acids (Lys, His, Arg, Arg) replaced by 4 alanines at the 3rd site

Also Known As:

Networked: 36 relevant articles (10 outcomes, 23 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Iyengar, S S: 2 articles (09/2017 - 07/2013)
2.	Jain, R K: 2 articles (09/2017 - 07/2013)
3.	Katyal, V K: 2 articles (09/2017 - 07/2013)
4.	Srinivasan, M: 2 articles (09/2017 - 07/2013)
5.	Damianou, Christakis: 2 articles (06/2017 - 12/2016)
6.	Papadopoulos, Nicos: 2 articles (06/2017 - 12/2016)
7.	Antman, Elliott M: 2 articles (03/2005 - 05/2004)
8.	Morrow, David A: 2 articles (03/2005 - 05/2004)
9.	Berioli, S: 2 articles (12/2001 - 01/2001)
10.	Fox, N L: 2 articles (12/2001 - 01/2001)

Related Diseases

1.	Myocardial Infarction 12/01/2001 - "In the Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT)-2 trial, 16 949 patients with acute myocardial infarction were randomly assigned a single weight-adjusted bolus of TNK-tPA or a 90-min infusion of rt-PA. " 01/21/1997 - "The thrombolysis in Myocardial Infarction (TIMI) 10A trial was a Phase 1, dose-ranging pilot trial designed to evaluate the pharmacokinetics, safety, and efficacy of TNK-TPA in patients with acute myocardial infarction. " 09/01/2001 - "Furthermore, the results of TNK-tPA clinical trials showed that even at the highest weight-optimized dosage of 50 mg, ICH rates were among the lowest reported in clinical trials of thrombolytics for acute myocardial infarction. " 11/01/1999 - "A total of 886 patients with acute myocardial infarction were randomized to receive either a single bolus of 30, 40, or 50 mg of TNK-tPA or front-loaded tPA in the Thrombolysis In Myocardial Infarction (TIMI) 10B trial. " 11/01/1999 - "Weight-adjusted dosing of TNK-tissue plasminogen activator and its relation to angiographic outcomes in the thrombolysis in myocardial infarction 10B trial. "
2.	ST Elevation Myocardial Infarction 09/01/2017 - "The findings of this study further reinforce the safety and efficacy of indigenous TNK-tPA in Indian patients presenting with STEMI, including high-risk sub-groups. " 12/01/2006 - "Citrated blood samples were obtained from 34 patients admitted with acute ST-elevation myocardial infarction (STEMI) treated with TNK-tpa. " 12/22/1998 - "In TIMI 10B, 886 patients with acute ST-elevation myocardial infarction presenting within 12 hours were randomized to receive either a single bolus of 30 or 50 mg TNK-tPA or front-loaded tPA and underwent immediate coronary angiography. " 01/21/1997 - "One hundred thirteen patients with acute ST-segment elevation myocardial infarction presenting within 12 hours and without contraindications to thrombolysis were enrolled and treated with a single bolus of TNK-TPA over 5 to 10 seconds with doses ranging from 5 to 50 mg. TNK-TPA demonstrated a plasma clearance of 151 +/- 55 mL/min and a half-life of 17 +/- 7 minutes. " 12/01/2006 - "In patients admitted with STEMI, thrombolytic therapy with TNK-tpa resulted in a significant short-lasting increase in specific types of XIIa (namely XIIaA), whereas other types of XIIa (XIIaR) were largely unaffected by this intervention."
3.	Stroke (Strokes) 06/01/2017 - "To provide a more realistic clinical environment of stroke, the study was conducted under realistic flow conditions and TNK-tPA concentrations. " 12/01/2016 - "To provide a more realistic clinical environment of stroke, the study was conducted under realistic flow conditions and TNK-tPA concentrations. " 06/01/2023 - "tPA-treated patients had an NIHSS (National Institutes of Health Stroke Scale) score of 9.2 versus 7.5 for TNK-tPA. " 06/01/2023 - "In June 2017, the Stroke Unit at Sundsvall County Hospital switched from tPA to TNK-tPA in standard clinical practice. " 12/01/2004 - "These data suggest that the combination of IV 7E3 F(ab')2 (4 hours) and IA TNK-tPA (6 hours) extends the therapeutic window of thrombolysis to 6 hours after stroke."
4.	Infarction (Infarctions) 12/01/2004 - "However, combination of IV 7E3 F(ab')2 (4 hours) and IV TNK-tPA (6 hours) or IA TNK-tPA (6 hours) alone failed to reduce infarct volume and improve neurological function compared with the saline-treated rats. " 09/29/2000 - "Although treatment with TNK-tPA of ischemic rats (n=12) at 4 h did not significantly (P=0.06) reduce infarct volume (28.6+/-3.0%), it also did not increase gross hemorrhage (25%) compared with the control group (25%). " 09/29/2000 - "Postischemic intracarotid treatment with TNK-tPA reduces infarct volume and improves neurological deficits in embolic stroke in the unanesthetized rat." 09/29/2000 - "Ischemic rats (n=10) treated with TNK-tPA at 2 h showed a significant (P<0.05) reduction of neurological deficits, body weight loss and infarct volume (22.8+/-2.1%) without an increase in gross hemorrhage (10%) compared with the non treated ischemic rats (25%). " 12/01/2004 - "The combination of IV 7E3 F(ab')2 (4 hours) and IA TNK-tPA (6 hours) significantly (P<0.05) reduced infarct volume and improved neurological functional deficits, which was associated with significant (P<0.05) reductions in the size of embolus at the origin of the occluded middle cerebral artery and in down-stream microvascular platelet and fibrin deposition, and enhanced microvascular patency compared with saline-treated rats. "
5.	Body Weight (Weight, Body) 11/01/1999 - "Thus, higher doses per unit body weight of TNK-tPA result in not only faster culprit artery flow, but also faster nonculprit, global, and post-PTCA flow, which may reflect earlier opening, reduced stunning, or improved microvascular function. " 11/01/1999 - "We hypothesized that higher doses of TNK-tissue plasminogen activator (tPA) per unit body weight would be related to improved flow at 90 minutes after thrombolytic administration. " 09/01/2001 - "However, data from TNK-tPA clinical trials suggest that body weight estimates can err by up to 20 kg (44 lb) without an increased risk of ICH or death. " 09/01/2001 - "In elderly female patients of low body weight, the use of weight-optimized TNK-tPA lowered the risk of ICH compared with the use of t-PA, expanding the potential use of thrombolytics to this high-risk patient population. " 09/01/2001 - "Weight-optimized TNK-tPA dosing requires body weight estimation, which may introduce the potential for medication error. "

Related Drugs and Biologics

1.	Tenecteplase
2.	Fibrin
3.	Fibrinolytic Agents (Antithrombotic Agents)
4.	Tissue Plasminogen Activator (Alteplase)
5.	Enoxaparin (Lovenox)
6.	Heparin (Liquaemin)
7.	Abciximab (ReoPro)
8.	disufenton sodium (NXY 059)
9.	TNK-tissue plasminogen activator
10.	MB Form Creatine Kinase

Related Therapies and Procedures

1.	Microbubbles
2.	Contraindications
3.	Therapeutics
4.	Thrombolytic Therapy
5.	Catheters